We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Oncology

Oncology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration
newsCT 影像high-grade serous ovarian cancer

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration

By MedXY|Jul 5, 2026

This study demonstrates that combining clinical variables with computed tomography radiomics features improves the prediction of recurrence-free survival in high-grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy and s

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
Gastroenterologyadjuvant chemotherapycirculating tumor DNA

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases

By MedXY|Jul 4, 2026

This study reveals that circulating tumor DNA (ctDNA) status after colorectal liver metastasis surgery predicts survival outcomes and benefits from adjuvant chemotherapy, guiding personalized treatment.

Global Variations in Concurrent Hysterectomy During Risk-Reducing Surgery for BRCA1/2 Carriers: An Integrated Quantitative and Qualitative Analysis
newsBRCA2risk-reducing surgery

Global Variations in Concurrent Hysterectomy During Risk-Reducing Surgery for BRCA1/2 Carriers: An Integrated Quantitative and Qualitative Analysis

By MedXY|Aug 18, 2026

This study reveals significant international differences in concurrent hysterectomy rates during risk-reducing salpingo-oophorectomy among BRCA1/2 variant carriers and explores underlying factors influencing surgical decisions across region

Symptom Prevalence in Lung Cancer Screening: Insights from the SUMMIT Study
newsĐánh giá rủi rolow-dose CT

Symptom Prevalence in Lung Cancer Screening: Insights from the SUMMIT Study

By MedXY|Jul 2, 2026

The SUMMIT study reveals that respiratory symptoms are common among lung cancer screening participants and associated with increased lung cancer diagnosis risk within one year, challenging conventional asymptomatic screening definitions.

Laparoscopic HIPEC as Consolidation Therapy in Advanced Epithelial Ovarian Cancer: Feasibility and Impact on Quality of Life
newsconsolidation therapyEpithelial ovarian cancer

Laparoscopic HIPEC as Consolidation Therapy in Advanced Epithelial Ovarian Cancer: Feasibility and Impact on Quality of Life

By MedXY|Aug 18, 2026

Laparoscopic HIPEC following upfront treatment in advanced epithelial ovarian cancer is feasible, safe, and preserves patient quality of life, offering a promising consolidation approach.

Helicobacter pylori Infection and Colorectal Cancer: Genetic Risk Links and Treatment Outcomes from Two Long-Term Randomized Trials
Gastroenterologycolorectal cancergenetic predisposition

Helicobacter pylori Infection and Colorectal Cancer: Genetic Risk Links and Treatment Outcomes from Two Long-Term Randomized Trials

By MedXY|Jul 1, 2026

Two large randomized trials reveal that Helicobacter pylori infection elevates colorectal cancer risk, particularly in individuals with specific bacterial virulence factors or high genetic susceptibility, and that eradication treatment may

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT
Hematology-Oncologyallo-SCTAML

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT

By MedXY|Jun 30, 2026

Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable surviva

Hypoxic Microenvironment Triggers Early Aggressive Progression in EGFR-Mutant Lung Adenocarcinoma
newsEGFR-mutant lung adenocarcinomahypoxia

Hypoxic Microenvironment Triggers Early Aggressive Progression in EGFR-Mutant Lung Adenocarcinoma

By MedXY|Jun 29, 2026

This study reveals that hypoxia in centrally located EGFR-mutant lung adenocarcinomas drives an alveolar lineage imbalance via the ZAKα-MAPK-c-Fos pathway, promoting early tumorigenesis. Therapeutic oxygenation can restore lineage balance a

Refining Prognostic Assessment in Perihilar Cholangiocarcinoma: The Clinical Utility of Dual Radial Margin Distance Cutoffs
General Surgeryperihilar cholangiocarcinomaprognosis

Refining Prognostic Assessment in Perihilar Cholangiocarcinoma: The Clinical Utility of Dual Radial Margin Distance Cutoffs

By MedXY|Jun 29, 2026

This study identifies dual cutoff values of 0 and 1 mm for radial margin distance in perihilar cholangiocarcinoma, providing a simple and effective stratification tool for postoperative recurrence risk and survival prediction.

PRO-PLATINUM Trial: Probiotic Modulation of the Microbiome to Enhance Outcomes in Ovarian Cancer Chemotherapy
newsovarian cancermicrobiome

PRO-PLATINUM Trial: Probiotic Modulation of the Microbiome to Enhance Outcomes in Ovarian Cancer Chemotherapy

By MedXY|Aug 18, 2026

The PRO-PLATINUM trial evaluates a novel 5-strain probiotic’s effect on gut and vaginal microbiome composition and clinical outcomes in ovarian cancer patients undergoing platinum chemotherapy, assessing safety, feasibility, and trans

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line
GastroenterologyChất ức chế kinase tyrosinehepatocellular carcinoma

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line

By MedXY|Jun 28, 2026

This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional

Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted Agents
Diabetes & EndocrinologyerythrocytosisRET inhibitors

Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted Agents

By MedXY|Jun 28, 2026

Erythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control r

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial
newscirculating tumor DNActDNA

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

By MedXY|Jun 28, 2026

The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring sho

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment
Gastroenterologyhepatocellular carcinomaimmunotherapy

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

By MedXY|Jun 27, 2026

NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer
newsExceptional responsePlatinum-sensitive

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

By MedXY|Aug 18, 2026

This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of s

Revisiting Level VII Lymph Node Metastasis in Medullary Thyroid Cancer: A Crucial Prognostic Subgroup
Diabetes & Endocrinologycancer stagingDi căn hạch cổ

Revisiting Level VII Lymph Node Metastasis in Medullary Thyroid Cancer: A Crucial Prognostic Subgroup

By MedXY|Jun 25, 2026

Level VII lymph node metastasis in medullary thyroid cancer signifies a highly aggressive phenotype with the poorest prognosis. Reclassifying level VII nodes as N1b improves prognostic accuracy and could refine staging and treatment strateg

Enhancing Lung Cancer Surgical Quality: Insights from the American College of Surgeons’ National Quality Improvement Collaborative
Clinical UpdatesChất lượng phẫu thuậtlung cancer

Enhancing Lung Cancer Surgical Quality: Insights from the American College of Surgeons’ National Quality Improvement Collaborative

By MedXY|Jun 25, 2026

This review synthesizes current evidence on lung cancer surgical quality improvement, highlighting the impactful American College of Surgeons Lung NODES Collaborative’s success in improving lymph node sampling compliance and broader a

Fibrosis-Driven Activation of Schwann Cells in Pancreatic Cancer: Unraveling the Nuclear Mechanosensing Pathway
GastroenterologyfibrosisMechanosensing

Fibrosis-Driven Activation of Schwann Cells in Pancreatic Cancer: Unraveling the Nuclear Mechanosensing Pathway

By MedXY|Jun 25, 2026

Pancreatic fibrosis activates Schwann cells via nuclear mechanosensing, promoting a protumorigenic environment that enhances pancreatic cancer progression, offering novel microenvironment-targeted therapeutic insights.

Cancer and Heart Failure in Scotland: Epidemiology, Interactions, and Prognostic Implications
Cardiologycancerepidemiology

Cancer and Heart Failure in Scotland: Epidemiology, Interactions, and Prognostic Implications

By MedXY|Jun 24, 2026

This review synthesizes evidence on the prevalence, incidence, and prognosis of cancer and heart failure comorbidity in Scotland, integrating recent cohort data and cardio-oncology research to inform clinical practice and future research di

newshead and neck cancerhypoglossal neuropathy

MDASI-HN Symptom Profiling for Early Risk Stratification of Hypoglossal Neuropathy in Oropharyngeal Cancer Survivors

By MedXY|Jun 18, 2026

This study found that patient-reported speech/voice and related head-and-neck symptoms can help predict hypoglossal neuropathy risk after oropharyngeal cancer treatment, supporting earlier surveillance with the MDASI-HN-NERVE score.

Prev
13 / 25
1…1112131415…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Browse by specialty

Open language-specific specialty feeds and department pages.

news6829 articlesCardiology1403 articlesClinical Updates1315 articlesOncology1176 articlesDiabetes & Endocrinology868 articlesNeurology834 articlesPublic Health605 articlesGastroenterology586 articles
Hematology-Oncology
513 articles
Pediatrics493 articles
Internal Medicine464 articles